Work

CAR T cells against the B cell receptor to precisely eliminate pathogenic B cells

Year: 2026

Type: article

Abstract: Chimeric antigen receptor (CAR) T cells, monoclonal antibodies, and bispecific antibodies (BsAbs) have transformed the treatment of B cell malignancies and are emerging as an exciting therapeutic option for autoimmune diseases. In particular, CAR T cells targeting CD19 (CART19) and BsAbs targeting CD3/CD19 and CD3/CD20 are now approved for B cell malignancies and are undergoing clinical trials for B cell-mediated autoimmune diseases. However, while potent, these therapies target pan-B cell markers and are, therefore, associated with a significant B cell aplasia and hypogammaglobulinemia.

Source: Molecular Therapy Oncology

DOI: 10.1016/j.omton.2026.201297

Authors: Audrey C. Bochi-Layec, Ivan J. Cohen, Jean Lemoine, Marco Ruella

Institutions: Hospital of the University of Pennsylvania, Abramson Cancer Center, University of Pennsylvania

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,900